Meta-analysis of FOLFIRINOX regimen as the first-line chemotherapy for locally advanced pancreatic cancer and borderline resectable pancreatic cancer
The study aimed to evaluate the effectiveness of the first-line chemotherapy FOLFIRINOX in treating pancreatic cancer. Pertinent studies were derived from the PubMed, Cochrane Library and EMBASE. The outcomes were analyzed according to resection rate and radical (R0) resection rate. Data were expressed as weighted commix proportions with 95% confidence intervals (CIs). Twenty-three studies, involving 968 patients with locally advanced pancreatic cancer (LAPC) and borderline resectable pancreatic cancer (BRPC), were examined. After treatment, 55% (95% CI 52–58%) of the patients underwent resection and 40% (95% CI 37–43%) underwent R0 resection, and the median overall survival ranged from 15.5 to 35.4 months, with a 10.0–27.1 months’ median progression-free survival. The meta-analysis shows that FOLFIRINOX, as the first-line therapy, has significant down-staging effects in patients with LAPC or BRPC, with a 40% R0 resection rate and the adverse events under control.
KeywordsPancreatic cancer FOLFIRINOX Resection
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.
Informed consent was obtained from all individual participants included in the study.
- 16.Peddi PF, Lubner S, McWilliams R, Tan BR, Picus J, et al. Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma. Jop. 2012;13:497–501.Google Scholar
- 29.Bai X, Su R, Ma T, Shen S, Li G, et al. Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China. Zhonghua Wai Ke Za Zhi. 2016;54:270–5.Google Scholar
- 34.Michelakos T, Pergolini I, Castillo CF, Honselmann KC, Cai L, et al. Predictors of resectability and survival in patients with borderline and locally advanced pancreatic cancer who underwent neoadjuvant treatment with FOLFIRINOX. Ann Surg. 2017.Google Scholar
- 35.Yoo C, Kang J, Kim KP, Lee JL, Ryoo BY, et al. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen. Oncotarget. 2017;8:46337–47.Google Scholar
- 36.Chapman BC, Gleisner A, Rigg D, Messersmith W, Paniccia A, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. Jop. 2018;19:75–85.Google Scholar
- 39.Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–2001 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.CrossRefGoogle Scholar
- 41.Gurusamy KS, Kumar S, Davidson BR, Fusai G. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database Syst Rev. 2014;2:CD010244.Google Scholar